Borderline Ovarian Tumors and Fertility: Understanding the Connection

When facing a diagnosis of borderline ovarian tumors (BOT) and fertility becomes a central concern, understanding your options can feel overwhelming. Borderline ovarian tumors present unique opportunities for fertility preservation that stem from their distinct biological behavior.

These unique tumors, affecting approximately 15% of all epithelial ovarian cancers, present a different landscape than their more aggressive counterparts. And here’s what matters most: they predominantly affect younger women, with 27 to 36% of cases occurring in women under 40 years old.

What Makes Borderline Ovarian Tumors Different?

Borderline ovarian cancer sits in a category all its own. Unlike benign cysts or invasive cancers, these tumors show cellular changes without the destructive invasion that characterizes true malignancy.

The distinction matters enormously for fertility. While invasive ovarian cancer often requires immediate, aggressive treatment that may compromise reproductive function, borderline tumors allow for a more measured approach.

Most borderline ovarian tumors are diagnosed at stage I (70 to 80%), compared to only 25% of invasive carcinomas. This early detection, combined with excellent survival rates of 98 to 100% for stage IA disease, creates opportunities for fertility preservation that simply don’t exist with other ovarian cancers.

The two main types behave differently:

Serous borderline tumors account for 53 to 65% of cases and are bilateral (affecting both ovaries) in 15 to 25% of patients. They’re more likely to spread to the peritoneum but tend to remain non-invasive.

Mucinous borderline tumors represent 32 to 42% of cases, are usually unilateral (affecting only one ovary), and tend to be larger (averaging 20 cm in diameter). While they recur less frequently than serous types, when they do recur outside the ovary, there’s a higher risk of invasive transformation.

Learn more: “Serous Borderline Tumor vs. Mucinous Borderline Tumor: What’s the Difference?”

Fertility-Sparing Surgery: Your Primary Preservation Option

Conservative surgery represents the gold standard for fertility preservation in borderline ovarian tumors. The approach balances cancer control with reproductive potential, offering real hope for future pregnancies.

Types of Fertility-Sparing Procedures

Unilateral salpingo-oophorectomy (USO) removes one ovary and fallopian tube while preserving the uterus and opposite ovary. Research reports a recurrence rate of 2.4% after unilateral salpingo-oophorectomy, supporting this as the preferred approach for many patients.

Ovarian cystectomy removes only the tumor while preserving healthy ovarian tissue. While ovarian cystectomy saves more ovarian function, research suggests it may carry a higher risk of local recurrence compared to removing the entire ovary. However, most recurrences remain borderline and can be treated successfully.

Bilateral cystectomy may be necessary when both ovaries are involved. One research study found no significant difference in recurrence rates between bilateral cystectomy and USO plus contralateral cystectomy.

Recurrence Risks and Management

The reality about recurrence needs honest discussion. Fertility-sparing surgery does increase recurrence risk compared to radical surgery. One landmark study found recurrence rates of 18.5% after fertility-sparing surgery compared to 4.7% after radical surgery.

But here’s the crucial point: most recurrences remain borderline rather than becoming invasive. According to research, recurrences typically occur in the remaining ovary and can often be treated with repeat conservative surgery. 

Most borderline tumor recurrences also happen within the first few years after surgery, emphasizing the importance of close surveillance during this period.

Pregnancy Outcomes After Treatment

Pregnancy outcomes after fertility-sparing surgery offer genuine reason for hope. Research consistently demonstrates that women who undergo conservative treatment maintain excellent reproductive potential, with studies showing encouraging pregnancy rates among those who attempt to conceive.

Most pregnancies occur spontaneously without the need for assisted reproductive technology. Research consistently shows that the majority of women who wish to conceive after conservative treatment are able to do so naturally.

Advanced Stage Disease and Fertility

Even women with advanced-stage borderline tumors may be candidates for fertility preservation. The key factor is the type of peritoneal implants.

Non-invasive implants can often be completely removed while preserving fertility. Complete removal of all visible disease is crucial for optimal outcomes.

Invasive implants require more careful consideration. While fertility-sparing surgery may still be possible, it requires individualized assessment and very close follow-up.

While advanced-stage disease presents additional challenges, fertility preservation may still be possible in carefully selected cases when complete removal of disease can be achieved.

Assisted Reproductive Technology Options

When natural conception proves difficult, several options exist:

In Vitro Fertilization (IVF)

IVF shows good results in borderline tumor survivors. One study reported a 40% pregnancy rate after IVF, with four recurrences among 25 patients but no deaths. The procedure appears safe for early-stage disease.

Some experts recommend waiting 1 to 2 years after surgery before pursuing IVF, balancing the higher early recurrence risk against potential spontaneous pregnancy. However, others argue that age-related fertility decline may outweigh this concern.

Intrauterine Insemination (IUI) 

IUI offers a less invasive first step for many women struggling to conceive after borderline tumor treatment. This procedure involves placing sperm directly into the uterus during ovulation, bypassing potential cervical factors and increasing the chance of fertilization.

For women with one remaining ovary and patent fallopian tubes, IUI combined with ovulation monitoring can be an effective and relatively low-cost option before considering more intensive treatments.

Ovarian Stimulation Considerations

The relationship between fertility drugs and borderline tumor risk remains debated. Some studies suggest associations with clomiphene use (a medication used to stimulate ovulation) while others find no clear causation.

Letrozole during ovarian stimulation may offer a safer alternative, potentially reducing estrogen exposure. One study found no stimulatory effect of hormones on borderline tumor cell cultures, suggesting gonadotropins may be safely used.

Egg Freezing

Oocyte cryopreservation represents an important backup option. This is particularly valuable for women who need more extensive surgery or those at higher recurrence risk.

Ex vivo oocyte retrieval — collecting eggs from removed ovaries during surgery — offers another possibility when standard retrieval isn’t feasible.

Special Considerations by Tumor Type

The histologic subtype of your borderline tumor significantly influences both treatment decisions and fertility outcomes. Understanding whether you have serous or mucinous disease helps guide the most appropriate surgical approach and follow-up plan.

Serous borderline tumors: These tumors recur more frequently but when they do recur, they typically remain borderline rather than becoming invasive cancer. However, the micropapillary variant deserves special attention — it’s more likely to present with invasive implants at diagnosis and may warrant more aggressive initial treatment or closer follow-up. When serous borderline tumors do have invasive implants, they’re usually the micropapillary type.

Bilateral cystectomy, or USO plus contralateral cystectomy, is often required in cases with bilateral involvement. 

Mucinous borderline tumors: Usually unilateral, these tumors allow for straightforward USO in most cases. However, when recurrence occurs, particularly outside the ovary, the risk of invasive transformation is higher. Some experts recommend completion surgery after childbearing for mucinous types with intraepithelial carcinoma or microinvasion.

Decision-Making and Long-Term Considerations

Several factors guide fertility preservation decisions in borderline ovarian tumors. 

Age and reproductive goals matter most — women under 35 with strong fertility desires often benefit most from conservative approaches. 

Tumor characteristics including stage, histologic subtype, and high-risk features like micropapillary pattern or microinvasion also influence treatment choices.

The extent of disease and ability to achieve complete removal affect surgical options, while conservative management requires committed long-term surveillance.

After childbearing, whether to remove the remaining ovary and uterus remains debated. Many experts favor watching serous tumors without high-risk features, intervening only if recurrence develops. For mucinous tumors with concerning features or microinvasion, removing the remaining reproductive organs may be recommended.

The psychological impact of living with higher recurrence risk shouldn’t be overlooked. Ovarian cancer support groups and counseling provide valuable resources for navigating these challenges.

The Impact of BOTs on Fertility 

Research continues to refine our understanding of borderline ovarian cancer and fertility preservation. Better molecular markers may eventually predict which tumors are most likely to recur or progress to invasion.

Improved fertility preservation techniques, including advances in egg and embryo freezing, continue expanding options for women facing these diagnoses.

The key message remains hopeful: most women with borderline ovarian tumors can preserve fertility while maintaining excellent survival outcomes. The combination of conservative surgery, close follow-up, and assisted reproductive technologies when needed offers multiple paths to motherhood.

Understanding the risks, benefits, and options empowers informed decision-making. With proper counseling and individualized care, the diagnosis of borderline ovarian tumors doesn’t have to mean the end of fertility dreams. The future remains bright for women facing this challenging but ultimately manageable diagnosis.